Clinical Trials Logo
  1. Home
  2. Transplant-Related Disorder
  3. NCT06393660

Treatment Use of the CliniMACS® CD34 TCR Alpha/Beta for Allogenic Transplant (Expanded Access Use)

Transplant-Related Disorder Clinical Trial

Official title:
Treatment Use of the CliniMACS® CD34 TCR Alpha/Beta to Prepare Cells for an Unlabeled Indication Using an HLA-Compatible Related or Unrelated Donor for Allogenic Transplant

Clinical Trial Summary

The purpose of this IDE protocol is to provide access to TCR Alpha/Beta+/CD19+ depleted allogeneic hematopoietic stem cell (HSC) in patients who require hematopoietic stem cell transplantation.

Clinical Trial Description

Allogeneic hematopoietic stem cell transplant (HSCT) is the only known curative therapy for a variety of non-malignant and malignant disorders1-4. Only about 25% of patients have an HLA-matched sibling and in about 16-75% (depending on ethnicity), a 10/10 HLA-matched unrelated donor can be identified. The use of mis-matched or haploidentical donors is associated with a higher risk of post-transplant mortality due to the development of severe graft versus host disease, graft failure and the development of infection due to the use of immunosuppression or T cell depletion. The protocol is designed to provide access to patients to the Clinimacs® CD34 TCR Alpha/Beta system to prepare cells for an unlabeled indication using an HLA-compatible related or unrelated donor for allogenic transplant. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06393660
Study type Expanded Access
Source University of Texas Southwestern Medical Center
Contact Victor Aquino, MD
Phone 214-648-3896
Email Victor.Aquino@utsouthwestern.edu
Status Available
Phase
View Details
See also
  Status Clinical Trial Phase
Completed NCT04985409 - Stepping Up: A Trial of Activity Monitoring Devices in Patients Undergoing Autologous Stem Cell Transplant N/A
Recruiting NCT05441436 - Neuropsychological and Biopsychosocial Evolution During Pediatric Transplantation: Pre/Post-stages and at 6 Months
Recruiting NCT05798286 - Quantra® System With the QPlus® Cartridge in Double-lung Transplantation N/A
Terminated NCT02434146 - Topical Phenylephrine Solution in Preventing Oral Mucosa in Bone Marrow Transplant Patients Receiving Cyclophosphamide and Total Body Radiation Therapy Phase 1/Phase 2
Withdrawn NCT03399227 - Liver Transplantation: Skeletal Effects
Recruiting NCT05967130 - Treatment Chronic UTI Post Kidney Transplant Phase 3
Recruiting NCT05600855 - Prevention of Severe Acute Graft-versus-host Disease in Adult Patients Using a daGOAT Model Phase 2
Recruiting NCT05599256 - Prevention of Severe Acute Graft-versus-host Disease in Pediatric Patients Using a daGOAT Model Phase 2
Completed NCT03811873 - Assessment of Vertebral Fracture Risk for First Time Liver Transplant Candidates N/A
Completed NCT05629923 - EVALUATION OF DIFFERENT PROPHYLACTIC INTERVENTIONS TOWARD COVID-19 IN SOLID ORGAN TRANSPLANT PATIENTS
Completed NCT03448679 - Albumin, COP and Endothelial Damage in Patients With ESLD Undergoing OLT N/A
Active, not recruiting NCT03769441 - Effect of Ferric Carboxymaltose on Exercise Capacity After Kidney Transplantation Phase 3
Active, not recruiting NCT03636412 - Improving Frailty With a Rigorous Ambulation Intervention in Lung Transplant Patients N/A
Recruiting NCT06066957 - Open Label Trial of Oral Letermovir for CMV Prophylaxis in Thoracic Transplant Recipients Phase 2
Recruiting NCT03015012 - Nutrigenomics, Overweight/Obesity and Weight Management Trial (NOW Trial) N/A
Not yet recruiting NCT06208137 - Using the Composite Immune Risk Score to Assess and Modulate the Patient's Post-transplant Immune Reconstitution. N/A
Not yet recruiting NCT04756622 - N-acetyl Cysteine for the Prevention of Oral Mucositis After Autologous Hematopoietic Cell Transplantation. Phase 3